BRÈVE

sur Biotest AG (isin : DE0005227201)

Dr. Jörg Schüttrumpf Resigns from Biotest AG Management Board

Graphique de l'évolution du cours de l'action Biotest AG (EBR:BIO).

Biotest AG has announced that Dr. Jörg Schüttrumpf will step down from his position as Chief Scientific Officer and member of the Management Board effective August 31, 2024. He will focus on his role as Chief Scientific Innovation Officer for the Grifols Group.

During his tenure, Dr. Schüttrumpf led the development of key products such as Fibrinogen, Trimodulin, and Yimmugo®, all integral to Biotest's Next Level expansion program and the Grifols Group pipeline.

Responsibilities formerly held by Dr. Schüttrumpf will now be managed by Mr. Janssen, CEO of Biotest AG. The company expressed its gratitude for his contributions and looks forward to continued collaboration within the Grifols Group.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de Biotest AG